Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 15/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095060 | 0.91 | HSD17B2 (0.37) | CCR9HSD17B2 | |
| SCHEMBL1095062 | 0.91 | HSD17B2 (0.37) | CCR9HSD17B2 | |
| SCHEMBL1095365 | 0.88 | HSD17B2 (0.39) | CCR9HSD17B2 | |
| SCHEMBL1095363 | 0.88 | HSD17B2 (0.39) | CCR9HSD17B2 | |
| SCHEMBL1095291 | 0.87 | CCR9 (0.40) | CCR9HSD17B2HTR1AHTR1DHTR1B | |
| SCHEMBL1094541 | 0.85 | CCR9 (0.37) | CCR9HSD17B2 | |
| SCHEMBL1094543 | 0.85 | CCR9 (0.37) | CCR9HSD17B2 | |
| SCHEMBL13343630 | 0.83 | HSD17B2 (0.38) | CCR9HSD17B2 | |
| SCHEMBL1094277 | 0.81 | HSD17B2 (0.37) | ALDH1A1CCR9HSD17B2HTR1AHTR1D | |
| SCHEMBL1094275 | 0.81 | HSD17B2 (0.37) | ALDH1A1CCR9HSD17B2HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718683-B2 | Triazolyl phenyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CHEMOCENTRYX, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039465-A1 | TRIAZOLYL PHENYL BENZENESULFONAMIDES | CCR9, CCR2, CCR1 | ALDH1A1 2935/4885CCR9 1/4885HSD17B2 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.